Skip to main content

Home/ MaRS/ Group items tagged Raphael

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Assunta Krehl

BioRegion Newsmakers | BioRegion News | Bioregionnews | GenomeWeb - 0 views

www.genomeweb.com/...bioregion-newsmakers-20

Raphael Hofstein MaRS Innovation Ilse Treurnicht

shared by Assunta Krehl on 07 Aug 09 - Cached
  • Toronto's MaRS Innovation Names Raphael (Rafi) Hofstein President and CEO
  • Raphael (Rafi) Hofstein has been appointed the president and CEO of MaRS Innovation, a Toronto commercialization center for three universities, 10 academic teaching hospitals, and the Ontario Institute for Cancer Research.
  • He succeeds Ilse Treurnicht, who served as interim managing director of MaRS Innovation, and is CEO of MaRS Discovery District.
  • Assunta Krehl on 07 Aug 09
     
    Raphael (Rafi) Hofstein has been appointed the president and CEO of MaRS Innovation.
Assunta Krehl

SCANSite.ca: MaRS places Israeli biotech veteran at helm - 0 views

www.scansite.ca/...aces_israeli_biotech_ve_1.html

Raphael Hofstein MaRS Innovation

shared by Assunta Krehl on 07 Aug 09 - Cached
  • MaRS places Israeli biotech veteran at helm
  • TORONTO – MaRS Innovation names Dr. Raphael Hofstein (pictured) as president and CEO. Dr. Hofstein comes to MaRS Innovation by way of Israel, where he was president and CEO of tech transfer company Hadasit Ltd.
  • “We are delighted to welcome Dr. Hofstein,” says Mary Jo Haddad, chair of MaRS Innovation, which is a subset of the Queen’s Park-sponsored innovation hub MaRS Discovery District.
  • ...2 more annotations...
  • “MaRS Innovation is a unique global initiative … to strengthen commercialization output,” says Dr. Hofstein.
  • Leading MaRS Innovation is a wonderful opportunity to do something remarkable.” Dr. Hofstein
  • Assunta Krehl on 07 Aug 09
     
    Toronto's MaRS Innovation Names Raphael (Rafi) Hofstein President and CEO.
Assunta Krehl

MaRS Innovation appoints president and CEO - University of Toronto -- News@UofT - 0 views

www.news.utoronto.ca/...oints-president-and-ceo-1.html

MaRS Innovation Toronto Discovery District Rafi Hofstein Tim McTiernan The Innovations Group

shared by Assunta Krehl on 15 Jun 09 - Cached
  • MaRS Innovation appoints president and CEO
  • A research commercialization leader from Israel, Dr. Raphael Hofstein, has been named president and CEO of the new MaRS Innovation initiative.
  • MI was created as a single, market-facing commercialization storefront for Toronto's university and health research institutions. Located in the MaRS Discovery District complex, with business development and administrative support from MaRS, MI will advance commercialization through industry partnerships, licensing and company creation. MaRS Innovation (MI) was founded in 2008 with $14.95 million in funding from the Government of Canada's Centres of Excellence for Commercialization and Research (CECR) Programme, matched by $10 million from the research partners. The MI partnership includes U of T, the 10 partner hospitals and health research institutes affiliated with the university, Ryerson University, the Ontario College of Art & Design, BioDisocovery Toronto, the Ontario Institute for Cancer Research and MaRS. Hofstein joins MaRS Innovation from his previous position as president and CEO of Hadasit Ltd., the technology transfer company of the Hadassah Medical Organization in Jerusalem.
  • ...3 more annotations...
  • "MaRS Innovation is a unique global initiative, and I must commend the institutional leaders in Toronto for pulling this innovation powerhouse together to strengthen commercialization output. In my experience, good science is the single most important ingredient for success in this business. Toronto is already known as one of the strongest science cities in the world, and it continues to grow. Leading MaRS Innovation is a wonderful opportunity to do something remarkable."
  • Dr. Tim McTiernan, assistant vice-president (research) and executive director of The Innovations Group (TIG), U of T's research commercialization operation, said Mars Innovation will provide significant benefits to U of T.
  • And he said that MI's role as a resource "is like putting a turbo charger on an engine. Having MI working with us and the other member organizations is a huge step in taking advantage of the enormous potential in the Toronto research community. Commercialization offices acting independently will not be able to manage in nearly as effective a manner as will be possible with the expertise of MaRS Innovation."
  • Assunta Krehl on 15 Jun 09
     
    Dr. Raphael Hofstein named president and CEO of the new MaRS Innovation initiative.
Assunta Krehl

Look who just landed on MaRS - The Globe and Mail - 0 views

www.theglobeandmail.com/...article1171592

Ralphael Hofstein MaRS Innovation

shared by Assunta Krehl on 08 Jun 09 - Cached
  • Look who just landed on MaRS
  • MaRS was known for just that – putting a collective roof over the heads of Canada's out-of-this-universe thinkers. Aside from hosting the unlikely duo of Arnold Schwarzenegger and Dalton McGuinty at a funding announcement two years ago, the centre seems enveloped in galactic silence.
  • corner of College and University
  • ...12 more annotations...
  • the country's most significant collection of scientific and medical researchers.
  • This week, a program called MaRS Innovation announced the appointment of its first full-time president, Raphael (Rafi) Hofstein, a Harvard-trained, Israeli biomedical wizard who wants to bring together companies, scientists and funding under one roof to create a special alchemy of science and shekels.
  • Since its inception, MaRS has focused on turning big ideas into commercial projects. The difference between the two entities is that pretty much anyone with an idea or discovery could come to MaRS for support, regardless of whether they had their “eureka” moment in a state-of-the-art research lab or in their garage. MaRS Innovation, a separate endeavour with its own board of directors, only works with researchers from its 14 partner institutions, which include some of the most prestigious universities and hospitals in Canada. The goal of that project is to do the kind of work those institutions would normally try to do in-house, but on a bigger scale and, the project's backers hope, with better results.
  • MaRS Innovation is very much in its infancy. Officially launched last June, the project is barely a year old, and the board of directors was only announced this February. It has secured about $25-million in funding over five years to be used for commercialization of projects.
  • Dr. Hofstein is giving himself two to three years to roll out a success story – be it the creation of a new small company founded on the back of a researcher's drug discovery and funded by a big pharmaceutical firm, or a new discovery that, packaged properly, attracts serious venture-capital money.
  • The federal government has also taken notice, naming MaRS Innovation as one of 11 new “Centres of Excellence for Commercialization and Research,” a designation that came with almost $15-million in funding.
  • California Governor Arnold Schwarzenegger speaks at MaRs with Premier Dalton McGuinty after a tour of the building in 2007.
  • Indeed, the MaRS Innovation model of pushing for commercial applications of research seems to be directly in line with the philosophy of the Conservative government, which clearly favours practical results when it comes to funding for scientific research.
  • But those tasks involve two separate skill sets, Mr. Tabrizi suggests, and may be much better suited to a place such as MaRS, where academic and industry heavyweights converge.
  • Many of MaRS's biggest partners are in health care, and Dr. Hofstein is jumping in with a list of priorities that includes focusing on stem-cell research and oncology.
  • MaRS itself has always been good at bringing people from various sectors together, but there's no guarantee that Dr. Hofstein's plan will work, especially in the two-to-three-year timeline he mentions when talking about a rollout date for the first MaRS Innovation projects.
  • Indeed, Mr. Tabrizi says some Silicon Valley insiders marvel at what MaRS Innovation is trying to do. “I think there's something innovative there,” he says. “Something different is being done.”
  • Assunta Krehl on 08 Jun 09
     
    MaRS Innovation announced the appointment of its first full-time president, Raphael (Rafi) Hofstein.
Assunta Krehl

Encycle Therapeutics Launches Ground-Breaking Chemistry Platform - MaRS Innovation - Ju... - 1 views

www.marsinnovation.com/...nd-breaking-chemistry-platform

Encycle Therapeutics MaRS Innovation commercialization Lifesciences Raphael Hofstein tenants Ontario Brain Institute funding

shared by Assunta Krehl on 29 Jun 12 - No Cached
  • Assunta Krehl on 29 Jun 12
     
    "Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for cyclizing peptides that promises to increase the efficiency of the early-stage drug discovery process."
Assunta Krehl

Encycle Therapeutics Launches Ground-Breaking Chemistry Platform - Canada Newswire - Ju... - 0 views

www.newswire.ca/...nd-breaking-chemistry-platform

Therapeutics Life Sciences & Healthcare IT Encycle Therapeutics MaRS Innovation Raphael Hofstein Tenants Ontario Brain Institute OBI Ontario Centre of Excellence OCE

shared by Assunta Krehl on 19 Jun 12 - No Cached
  • Assunta Krehl on 19 Jun 12
     
    "Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for cyclizing peptides that promises to increase the efficiency of the early-stage drug discovery process."
1 - 6 of 6
Showing 20▼ items per page